TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04539522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three-dimensionally corrective exercise for scoliosis
Description: Three-dimensionally corrective exercise for scoliosis is based the theory of physiotherapeutic scoliosis specific exercises, which focus on 3-dimension self-correction and consists of two parts:1)outpatient treatment including stretching, three-dimensional auto-correction(combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.), balance and stability training, combined with manual fascia relaxation therapy, and and breathing training; 2)family rehabilitation: combines self-correcting gymnastics with daily posture management, etc., forming the individual exercise approach for each patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: Conventional exercise consists a series of spine exercises focusing on core strength training.
Study: NCT04264650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an mHealth intervention
Description: The Care \& Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an mHealth intervention
Description: The Care \& Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program
Study: NCT04111016

Intervention type: BEHAVIORAL
Intervention: Integrated child stimulation, nutrition, lead, arsenic, WASH intervention
Description: The content of the intervention curriculum was developed considering the needs of the specific ages of the children attending the group, as well as the feasibility of delivering the package in the community. The pregnancy module encompasses information on significance of prenatal care for child development, physiological symptoms and solutions, maternal diet, education on kangaroo mother care (KMC), breast feeding, thinking healthy, hygiene, and lead and arsenic prevention. The curriculum for lactating mothers focuses on specialized messages for 4 age groups of children: 0-5 months, 6-11 months, 12-18 months and 19-24 months. The overall package includes information regarding WASH, psychosocial stimulation, nutrition, maternal mental health, lead and arsenic. As research evidence showed that psychosocial stimulation provided for 10 or 12 months can significantly improve child development, the psychosocial stimulation component is included in every fortnightly session.
Study: NCT02092051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with DexCom G4 platina
Study: NCT00951522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo in sterile saline
Study: NCT02671539

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2.REP1
Description: single subretinal injection
Study: NCT02002936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB C-1101
Description: SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
Study: NCT02209948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT02386215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV self-test
Description: Two self-test kits will be distributed to women, each containing the following:~* One standard OraQuick ADVANCE I/II test kit~* Written pre-test information including test instructions in written and pictorial form~* A phone number that participants can call to obtain additional information~* Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing
Study: NCT01067599

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low nicotine
Description: Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium nicotine
Description: Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High nicotine
Description: Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
Study: NCT04095663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Colectomy
Description: Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise.
Study: NCT02218086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slackline
Description: Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slackline
Description: Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wobbling Board
Description: Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wobbling Board
Description: Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-training
Description: First investigation of the beginners with less than 1 hour experience with slacklining.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fix visual anchor
Description: Professionals have to gaze at a fixed visual anchor during the slacklining.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moving visual anchor
Description: Professionals have to gaze at a moving visual anchor during the slacklining.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-training
Description: Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slackline vs. standing-on-1-leg vs. control
Description: beginners have to train 9 times \~15minutes within y few weeks.
Study: NCT01437098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDT-2111 CoreValve for TAVI
Description: CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
Study: NCT01330589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-active placebo for 7 days: PO/TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-active placebo for 7 days: PO/TID
Study: NCT01187446

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total skin electron beam therapy (TSEBT)
Description: TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
Study: NCT02118311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
Study: NCT01330589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. Johns Wort
Description: For 7 days: 300mg PO/TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. Johns Wort
Description: For 7 days: 300mg PO/TID
Study: NCT01005420

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Powder
Description: The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
Study: NCT04437329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, nedaplatin, fluorouracil
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, cisplatin, fluorouracil
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
Study: NCT02118311

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
Study: NCT04437329

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated-radiotherapy
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
Study: NCT00686257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total face mask (interface for NPPV)
Description: NPPV is applied by this mask, as long as NPPV is received.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfort full or RT040 oronasal mask (interface for NPPV)
Description: NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
Study: NCT04437329

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity modulated-radiotherapy
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
Study: NCT01066546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon tablet for oral administration
Description: 10 mg TID for Week 1, followed by 20 mg TID for remainder of study
Study: NCT01966406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No nasogastric tube
Study: NCT01030237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 114657
Description: 1 drop both eyes four times a day for 6 weeks
Study: NCT02413086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early-stage amputation
Description: Individuals with DFU were given early-stage amputation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early-stage amputation
Description: Individuals with DFU were given early-stage amputation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amputation
Description: Individuals with DFU were given amputation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amputation
Description: Individuals with DFU were given amputation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External herbs chitosan
Description: Wound was given external herbs chitosan after amputation.
Study: NCT01030237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soothe XP Lubricant Eye Drops
Description: 1 drop both eyes four times a day for 6 weeks
Study: NCT01380145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recMAGE-A3 Protein + AS15 Adjuvant
Description: recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
Study: NCT04707807

Intervention type: DIAGNOSTIC_TEST
Intervention: IIEF-5
Description: IIEF-15 form will be filled out by all participants

Intervention type: DIAGNOSTIC_TEST
Intervention: IIEF-5
Description: IIEF-15 form will be filled out by all participants
Study: NCT05097638

Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry
Description: Patient do spirometry
Study: NCT01579799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-lysine
Description: Dose finding study for L-lysine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-lysine
Description: Dose finding study for L-lysine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-lysine
Description: Dose finding study for L-lysine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-lysine
Description: Dose finding study for L-lysine
Study: NCT02413086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External herbs chitosan
Description: Wound was given external herbs chitosan after amputation.
Study: NCT02634307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 8700
Description: Administered as specified in the treatment arm.
Study: NCT02656147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR γδT
Description: Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR γδT
Description: Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR γδT
Description: Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
Study: NCT00586755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive Induction-BMT
Description: Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
Study: NCT01214200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BiPAP)
Description: This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
Study: NCT00667017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RFT5-dgA immunotoxin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorescence activated cell sorting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study: NCT01187446

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total skin electron beam therapy (TSEBT)
Description: TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
Study: NCT01080066

Intervention type: OTHER
Intervention: No Intervention
Description: Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m\^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m\^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
Study: NCT01194843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological serum
Description: 40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
Study: NCT02413086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional gauze
Description: Wound was given traditional gauze after amputation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional gauze
Description: Wound was given traditional gauze after amputation.
Study: NCT06277349

Intervention type: DEVICE
Group type: OTHER
Intervention: Toric multifocal IOL
Description: Implant of Multifocal toric intraocular lens only
Study: NCT02910492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enLighten Laser
Description: Dual-pulse duration laser for the treatment of skin rejuvenation
Study: NCT01497665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN1005
Description: 650 mg/m2 IV every 3 weeks
Study: NCT05801016

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Emerging Technologies and Training in Neurosciences
Description: Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Emerging Technologies and Training in Neurosciences
Description: Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall
Study: NCT00514592

Intervention type: OTHER
Intervention: New Guidelines
Description: New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
Study: NCT04004026

Intervention type: OTHER
Intervention: Assesment
Description: 3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
Study: NCT02607735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet administered orally once daily with food
Study: NCT04585113

Intervention type: RADIATION
Intervention: CT-scanning
Description: All participants will receive dual-energy CT scanning and cone-beam CT scanning prior surgery.
Study: NCT00066443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Dose escalation schedule A\&B = 6mg fixed dose once per cycle on day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
Study: NCT02485405

Intervention type: OTHER
Intervention: Trier social stress test
Description: Volunteers perform Trier social stress test
Study: NCT06277349

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-toric multifocal IOL
Description: Implant of non-toric multifocal lens plus incisional surgery
Study: NCT02280824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CA-TAVR
Description: Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplatzer Duct Occluder
Study: NCT03087942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: 450 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW39A
Description: 450 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW39A2107
Description: 450 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW39A2107
Description: 450 mg